Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

NCT07016230 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Metastatic/Locally Advanced Small-Cell Lung Cancer
Metastatic/Locally Advanced Poorly Differentiated NEC
Metastatic/Locally Advanced High-grade MTC

Interventions

DRUG: Tarlatamab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]